| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
|
Agliardi, Giulia
|
|
|
12 |
1 |
p. e57-e67
|
artikel
|
| 2 |
Air pollution and venous thromboembolism: current knowledge and future perspectives
|
Swan, Dawn
|
|
|
12 |
1 |
p. e68-e82
|
artikel
|
| 3 |
Antifibrinolytics do not add to the benefits of platelet transfusion
|
Schiffer, Charles A
|
|
|
12 |
1 |
p. e2-e3
|
artikel
|
| 4 |
Building health advocacy campaigns to engage sexual and gender minority populations with health care
|
Schneidman, Jillian
|
|
|
12 |
1 |
p. e11-e13
|
artikel
|
| 5 |
Correction to Lancet Haematol 2024; published online Dec 4. https://doi.org/10.1016/S2352-3026(24)00319-3
|
|
|
|
12 |
1 |
p. e9
|
artikel
|
| 6 |
Haematology and climate change
|
The Lancet Haematology,
|
|
|
12 |
1 |
p. e1
|
artikel
|
| 7 |
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
|
Alderuccio, Juan Pablo
|
|
|
12 |
1 |
p. e23-e34
|
artikel
|
| 8 |
Oreofe Odejide—aiming to raise the bar in haematology care
|
Kirby, Tony
|
|
|
12 |
1 |
p. e10
|
artikel
|
| 9 |
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
|
Mina, Roberto
|
|
|
12 |
1 |
p. e45-e56
|
artikel
|
| 10 |
Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma
|
Visram, Alissa
|
|
|
12 |
1 |
p. e6-e8
|
artikel
|
| 11 |
Re-energising therapy options in sickle cell disease: the mitapivat phase 2 trial results
|
Rai, Parul
|
|
|
12 |
1 |
p. e5-e6
|
artikel
|
| 12 |
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial
|
Idowu, Modupe
|
|
|
12 |
1 |
p. e35-e44
|
artikel
|
| 13 |
The challenges of detecting early efficacy signals in lymphoma trials
|
Hoster, Eva
|
|
|
12 |
1 |
p. e3-e5
|
artikel
|
| 14 |
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
|
|
|
|
12 |
1 |
p. e14-e22
|
artikel
|
Tijdschrift beschrijving